The myocardial contraction fraction is superior to ejection fraction in predicting survival in patients with AL cardiac amyloidosis

Amyloid

Volumn 22, Issue 1, 2015, Pages 61-66

  Tendler, Amanda ^a   Helmke, Stephen ^a   Teruya, Sergio ^a   Alvarez, Julissa ^a   Maurer, Mathew S ^a  

^a Department of Medicine   (United States)

Author keywords

Cardiac amyloidosis; Echocardiography; Myocardial contraction faction; Survival

Indexed keywords

AMYLOID; BRAIN NATRIURETIC PEPTIDE; PREALBUMIN; TROPONIN I; AMYLOID L, HUMAN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR MORTALITY; COMORBIDITY; DIABETES MELLITUS; FEMALE; FOLLOW UP; HEART AMYLOIDOSIS; HEART CONTRACTION; HEART EJECTION FRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; HUMAN; HYPERTENSION; LIGHT CHAIN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MYOCARDIAL CONTRACTION FRACTION; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; SURVIVAL; SURVIVAL RATE; TREATMENT DURATION; TWO DIMENSIONAL ECHOCARDIOGRAPHY; AMYLOIDOSIS; ECHOGRAPHY; GENETICS; KAPLAN MEIER METHOD; MORTALITY; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AMYLOID; AMYLOIDOSIS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL CONTRACTION; PROPORTIONAL HAZARDS MODELS; STROKE VOLUME;

EID: 84927161377     PISSN: 13506129     EISSN: 17442818     Source Type: Journal    
DOI: 10.3109/13506129.2014.994202     Document Type: Article

References (27)

1. Rapezzi C, Merlini G, Quarta CC, Riva L, Longhi S, Leone O, Salvi F, et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation 2009;120:1203-12.
2. Ruberg FL, Maurer MS, Judge DP, Zeldenrust S, Skinner M, Kim AY, Falk RH, et al. Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS). Am Heart J 2012;164:222-8.
3. Liao R, Jain M, Teller P, Connors LH, Ngoy S, Skinner M, Falk RH, et al. Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts. Circulation 2001;104:1594-7.
4. King DL, El-Khoury Coffin L, Maurer MS. Myocardial contraction fraction: A volumetric index of myocardial shortening by freehand three-dimensional echocardiography. J Am Coll Cardiol 2002;40: 325-9.
5. Lindqvist P, Olofsson BO, Backman C, Suhr O, Waldenstrom A. Pulsed tissue Doppler and strain imaging discloses early signs of infiltrative cardiac disease: A study on patients with familial amyloidotic polyneuropathy. Eur J Echocardiog 2006;7:22-30.
6. Koyama J, Falk RH. Prognostic significance of strain Doppler imaging in light-chain amyloidosis. JACC Cardiovasc Imag 2010;3: 333-42.
7. Rudski LG, Lai WW, Afilalo J, Hua L, Handschumacher MD, Chandrasekaran K, Solomon SD, et al. Guidelines for the echocardiographic assessment of the right heart in adults: A report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr 2010;23:685-713; quiz 86-8.
8. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, Gutgesell H, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989;2:358-67.
9. de Simone G, Devereux RB, Ganau A, Hahn RT, Saba PS, Mureddu GF, Roman MJ, et al. Estimation of left ventricular chamber and stroke volume by limited M-mode echocardiography and validation by two-dimensional and Doppler echocardiography. Am J Cardiol 1996;78:801-7.
10. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986; 57:450-8.
11. Rapezzi C, Riva L, Quarta CC, Perugini E, Salvi F, Longhi S, Ciliberti P, et al. Gender-related risk of myocardial involvement in systemic amyloidosis. Amyloid 2008;15:40-8.
12. Connors LH, Prokaeva T, Lim A, Theberge R, Falk RH, Doros G, Berg A, et al. Cardiac amyloidosis in African Americans: comparison of clinical and laboratory features of transthyretin V122I amyloidosis and immunoglobulin light chain amyloidosis. Am Heart J 2009;158:607-14.
13. Kristen AV, Perz JB, Schonland SO, Hegenbart U, Schnabel PA, Kristen JH, Goldschmidt H, et al. Non-invasive predictors of survival in cardiac amyloidosis. Eur J Heart Fail 2007;9:617-24.
14. Austin BA, Duffy B, Tan C, Rodriguez ER, Starling RC, Desai MY. Comparison of functional status, electrocardiographic, and echocardiographic parameters to mortality in endomyocardial-biopsy proven cardiac amyloidosis. Am J Cardiol 2009;103:1429-33.
15. Migrino RQ, Harmann L, Woods T, Bright M, Truran S, Hari P. Intraventricular dyssynchrony in light chain amyloidosis: A new mechanism of systolic dysfunction assessed by 3-dimensional echocardiography. Cardiovasc Ultrasound 2008;6:40.
16. Bhuiyan T, Helmke S, Patel AR, Ruberg FL, Packman J, Cheung K, Grogan D, et al. Pressure-volume relationships in patients with transthyretin (ATTR) cardiac amyloidosis secondary to V122I mutations and wild-type transthyretin: Transthyretin Cardiac Amyloid Study (TRACS). Circulation Heart Fail 2011;4:121-8.
17. Bellavia D, Pellikka PA, Al-Zahrani GB, Abraham TP, Dispenzieri A, Miyazaki C, Lacy M, et al. Independent predictors of survival in primary systemic (Al) amyloidosis, including cardiac biomarkers and left ventricular strain imaging: an observational cohort study. J Am Soc Echocard 2010;23:643-52.
18. Buss SJ, Emami M, Mereles D, Korosoglou G, Kristen AV, Voss A, Schellberg D, et al. Longitudinal left ventricular function for prediction of survival in systemic light-chain amyloidosis: incremental value compared with clinical and biochemical markers. J Am Coll Cardiol 2012;60:1067-76.
19. Perlini S, Salinaro F, Musca F, Mussinelli R, Boldrini M, Raimondi A, Milani P, et al. Prognostic value of depressed midwall systolic function in cardiac light-chain amyloidosis. J Hypertens 2014;32: 1121-31.
20. King DL, Coffin Lel K, Maurer MS. Noncompressibility of myocardium during systole with freehand three-dimensional echocardiography. J Am Soc Echocardiograph 2002;15:1503-6.
21. Chuang ML, Gona P, Salton CJ, Yeon SB, Kissinger KV, Blease SJ, Levy D, et al. Usefulness of the left ventricular myocardial contraction fraction in healthy men and women to predict cardiovascular morbidity and mortality. Am J Cardiol 2012;109: 1454-8.
22. Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation 2005;112:2047-60.
23. Mishra S, Guan J, Plovie E, Seldin DC, Connors LH, Merlini G, Falk RH, et al. Human amyloidogenic light chain proteins result in cardiac dysfunction, cell death, and early mortality in zebrafish. Am J Physiol 2013;305:H95-103.
24. Shi J, Guan J, Jiang B, Brenner DA, Del Monte F, Ward JE, Connors LH, et al. Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway. Proc Natal Acad Sci USA 2010;107: 4188-93.
25. Karamitsos TD, Piechnik SK, Banypersad SM, Fontana M, Ntusi NB, Ferreira VM, Whelan CJ, et al. Noncontrast: T1 mapping for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imag 2013; 6:488-97
26. Sun JP, Stewart WJ, Yang XS, Donnell RO, Leon AR, Felner JM, Thomas JD, et al. Differentiation of hypertrophic cardiomyopathy and cardiac amyloidosis from other causes of ventricular wall thickening by two-dimensional strain imaging echocardiography. Am J Cardiol 2009;103:411-15.
27. Ford WR, Menon V, Bhambhani A, Liyanage R, Khan MI, Jugdutt BI. Changes in myocardial density during postinfarction healing: Effect on estimation of in vivo left ventricular mass by echocardiographic imaging. Canad J Physiol Pharmacol 1997;75:1075-82.